Home Newsfeeds CJS Securities Upgrades Vicor to Market Outperform

CJS Securities Upgrades Vicor to Market Outperform

CJS Securities analyst Jonathan Tanwanteng upgrades Vicor (NASDAQ:VICR) from Market Perform to Market Outperform.

byBenzinga Newsdesk

October 26, 2022

1 minute read

CJS Securities analyst Jonathan Tanwanteng upgrades Vicor (NASDAQ:VICR) from Market Perform to Market Outperform.

Tesla, McDonald’s And 3 Stocks To Watch Heading Into Monday

By Lisa Levin

April 3, 4:01 AM

With US futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:

MCD

FDA
News

Eli Lilly Says Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly’s Phase 3 Monotherapy Atopic Dermatitis Trials

By Benzinga Newsdesk

September 8, 8:18 AM

New, late-breaking data show lebrikizumab responders reported long-lasting results at one year of treatment across measures of improvement in skin clearance, itch and disease extent and severity Results suggest less

LLY

Ascendis Pharma To Present New Data And Updated Results From Phase 1/2 IL-Believe Trial At ASCO 2024

By Benzinga Newsdesk

June 3, 4:05 PM

- 40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated with TransCon IL-2 β/γ in combination with TransCon TLR7/8 Agonist exhibited

ASND